Children's Cancer Institute of Australia

Poor neuroblastoma outcome involves high-level multidrug transporter expression

Published in Cancer Law Weekly, June 3rd, 2006

Recent research from Australia has documented an association of high-level multidrug transporter gene MRP1 (ABCC1) expression with poor clinical outcome in a large prospective study of primary neuroblastoma.

"We have previously shown in a retrospective study that expression of MRP1 is associated with outcome in neuroblastoma. We have now undertaken a prospective analysis to examine the independent prognostic significance of MRP1 expression in a large cohort of primary untreated neuroblastomas," wrote M. Haber and colleagues, Children's Cancer Institute of Australia.

"Two hundred nine diagnostic neuroblastoma samples from patients prospectively...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Cancer Law Weekly

Source: Cancer Law Weekly (2006-06-03)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry